J&J maintains €1.75 billion offer for Crucell but shareholders want more
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has made official its €1.75 billion bid for Crucell, but the Dutch biotech company's shareholders, hoping for a raised offer, could yet derail the US healthcare giant's plans.